Key facts
- Curileum Discovery’s last known valuation is $22.4M (Jan 2025).
- It has raised $4.7M; the latest was Later Stage VC ($2.1M) in Jan 2025.
- Notable investors include Innovate UK, Deltam Family Holdings, Oxford Technology Management.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Curileum Discovery
- ·The full record, as it builds
Funding rounds
No funding rounds for Curileum Discovery are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Curileum Discovery
Developer of an intestinal disease therapeutics designed to restore health to the gut barrier. The company's therapeutics correct imbalances in cell number and composition of the mucosal barrier while eliminating precancerous cells and dampening chronic inflammation in IBD and obesity, enabling patients to protect themselves against the consequences of harmful bacteria and chronic gastrointestinal diseases.
- Sector
- Healthcare
- HQ
- Harrow, United Kingdom
- Founded
- 2013
- Employees
- 3
- Website
- curileum.com/
- Ownership
- Privately Held (backing)
Curileum Discovery doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Curileum Discovery shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Curileum Discovery in its N-PORT filings yet. We sweep new filings monthly.